Search - tctmd.com

Displaying 41 - 60 of 94

Sort: Relevancy | Date

Presentation TCT 2017

Amulet: Data Synthesis and Ongoing Trials

Presenter: William A. Gray, Vivek Y. Reddy, Fabian Nietlispach

October 30, 2017

Presentation TCT 2017

WATCHMAN: Data Synthesis and Ongoing Trials

Presenter: William A. Gray, Vivek Y. Reddy

October 30, 2017

Presentation TCT 2017

Do the PIONEER and RE-DUAL Results Alter LAA Closure Decisions?

Presenter: William A. Gray, Vivek Y. Reddy, C. Michael Gibson

October 30, 2017

Presentation TCT 2017

Should the Improved Results With NOACs Compared to Warfarin Change LAA Closure Decisions?

Presenter: William A. Gray, Vivek Y. Reddy, Kurt Huber

October 30, 2017

Presentation TCT 2017

Topic 1: How Should We Evaluate Technologies in Their Infancy? TAVR, Renal Denervation, BVS, LAA Closure, Mechanical Circulatory Support, and More

Presenter: Robert A. Byrne, Gregg W. Stone, Aaron V. Kaplan

October 30, 2017

Presentation TCT 2017

Debate: LAA Closure Should Be Considered in Most Patients With Nonvalvular Atrial Fibrillation!

Presenter: Christopher B. Granger, Horst Sievert, Maurice Buchbinder

October 30, 2017

Presentation TCT 2017

Debate: LAA Closure Should Be Considered Only As a Last Resort Option!

Presenter: Christopher B. Granger, Horst Sievert, John M. Mandrola

October 30, 2017

Presentation TCT 2017

LAA Closure Plus ... TAVR, MitraClip, and More

Presenter: Christopher B. Granger, Horst Sievert, Samir R. Kapadia

October 30, 2017

Presentation TCT 2017

Catheter Ablation and/or LAA Closure for Atrial Fibrillation: Competitive or Complementary?

Presenter: Christopher B. Granger, Horst Sievert, Vivek Y. Reddy

October 30, 2017

Presentation TCT 2017

Current Guidelines and Recommendations for LAA Closure in Nonvalvular Atrial Fibrillation

Presenter: Christopher B. Granger, Horst Sievert, Pascal Vranckx

October 30, 2017

Presentation TCT 2017

High-Risk AF Patients: Changing the Emphasis From Stroke Prevention to Stroke and Hemorrhagic Complication Avoidance

Presenter: Christopher B. Granger, Horst Sievert, Michael D. Ezekowitz

October 30, 2017

Presentation TCT 2017

How to Calculate Stroke and Bleeding Risk in Clinical Practice

Presenter: Christopher B. Granger, Horst Sievert, Ted Feldman

October 30, 2017

Presentation TCT 2017

Strengths and Limitations of VKA and NOACs in Clinical Practice

Presenter: Christopher B. Granger, Horst Sievert

October 30, 2017

Presentation TCT 2017

Origin of Thromboemboli in Atrial Fibrillation: Valvular vs Non-Valvular AF, Large vs Small Left Atria, and Other Considerations

Presenter: Christopher B. Granger, Horst Sievert, Renu Virmani

October 30, 2017

Presentation TCT 2017

Case #6: LAA Closure - Device Embolization (With Discussion)

Presenter: Mauricio G. Cohen, Simon R. Dixon, Krzysztof Bartus

October 30, 2017

Presentation TCT 2017

LAA Closure III: Postprocedure and Beyond

Presenter: Russell A. Brandwein

October 30, 2017

Presentation TCT 2017

LAA Closure II: From Consultation to Procedure

Presenter: Russell A. Brandwein, Jessica Forman

October 30, 2017

Presentation TCT 2017

LAA Closure I: From Referral to Consultation

Presenter: Russell A. Brandwein, Lindsay Thomas

October 30, 2017

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for October 2017

Shelley Wood

October 29, 2017

Presentation TCT 2017

LAA Closure: Underused Therapy in Patients With High Bleeding Risk

Presenter: David Hildick-Smith, Lars Sondergaard, Robert A. Byrne

October 29, 2017

Advertisement

Amulet: Data Synthesis and Ongoing Trials

WATCHMAN: Data Synthesis and Ongoing Trials

Do the PIONEER and RE-DUAL Results Alter LAA Closure Decisions?

Should the Improved Results With NOACs Compared to Warfarin Change LAA Closure Decisions?

Topic 1: How Should We Evaluate Technologies in Their Infancy? TAVR, Renal Denervation, BVS, LAA Closure, Mechanical Circulatory Support, and More

Debate: LAA Closure Should Be Considered in Most Patients With Nonvalvular Atrial Fibrillation!

Debate: LAA Closure Should Be Considered Only As a Last Resort Option!

LAA Closure Plus ... TAVR, MitraClip, and More

Catheter Ablation and/or LAA Closure for Atrial Fibrillation: Competitive or Complementary?

Current Guidelines and Recommendations for LAA Closure in Nonvalvular Atrial Fibrillation

High-Risk AF Patients: Changing the Emphasis From Stroke Prevention to Stroke and Hemorrhagic Complication Avoidance

How to Calculate Stroke and Bleeding Risk in Clinical Practice

Strengths and Limitations of VKA and NOACs in Clinical Practice

Origin of Thromboemboli in Atrial Fibrillation: Valvular vs Non-Valvular AF, Large vs Small Left Atria, and Other Considerations

Case #6: LAA Closure - Device Embolization (With Discussion)

LAA Closure III: Postprocedure and Beyond

LAA Closure II: From Consultation to Procedure

LAA Closure I: From Referral to Consultation

TCTMD’s Top 10 Most Popular Stories for October 2017

LAA Closure: Underused Therapy in Patients With High Bleeding Risk

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content